Jim68 schreef op 4 september 2020 14:19:
Ruconest is de corona aspirine
Het coronavirus is een blijver net als influenza.
De griepprik werkt niet 100% net als straks een corona vaccin niet 100% werkt.
Voor hoofdpijn hebben we aspirines, voor o.a. de longonsteking hebben we Ruconest
Pharming announces the publication of data from a compassionate use programme of RUCONEST® in COVID-19 patients in a peer-reviewed journal
Leiden, The Netherlands, 17 August 2020: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use programme of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.
As reported on 21 April 2020, following treatment with RUCONEST®, fever resolved in four of the five patients within 48 hours, and laboratory markers of inflammation decreased significantly (CRP, IL-6). Soon thereafter, four of the five patients were discharged from the hospital as fully recovered. One patient had increased oxygen requirement and was temporarily transferred to the ICU for intubation but over the subsequent days made a full recovery.
Given this was a small case series, the outcomes were retrospectively compared to a matched control population of 15 patients. Baseline characteristics, admission laboratory parameters and treatments administered were similar in both groups. Both groups received standard of care as well as experimental therapies including antiviral and anti-cytokine directed medications. However, 8/15 (53%) patients in the control population required mechanical ventilation and 4 of these patients died, compared to only 1 (20%) requiring mechanical ventilation and no deaths in the RUCONEST® group. Overall, treatment with, in total five normal dose equivalents of RUCONEST® over 48h was well-tolerated. The full publication is available on the company’s website
www.pharming.comPharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®
Highlights:
• Clinical trial follows encouraging results from five patients with confirmed COVID-19 infections administered RUCONEST® to treat the related severe pneumonia
• First patient at the University Hospital Basel, Basel, Switzerland, with confirmed COVID-19 infection has been enrolled in a clinical trial to investigate the use of RUCONEST® to prevent severe SARS-CoV-2 infection in hospitalised patients with COVID-19
• Study to be extended to additional clinical centres in Switzerland, Mexico and Brazil
• Additional study in multiple centres in the US in final stages of preparation
www.prnewswire.co.uk/news-releases/ph...